Drugs News and Research

RSS

Researchers identify potential drug target for treatment of Alzheimer's disease

Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimer's disease: a receptor that is embedded in the membrane of neurons and other cells.

21 Apr 2010

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

Phenomix Corporation today announced positive top-line results from a six-month Phase 3 study comparing dutogliptin 400mg and 200mg once daily as monotherapy versus placebo for the treatment of patients with Type 2 diabetes mellitus. Dutogliptin is Phenomix' internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor.

20 Apr 2010

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that bafetinib (formerly known as INNO-406) has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of chronic myeloid leukemia (CML).

20 Apr 2010

Pharmacies launch Dispose My Meds campaign to help consumers safely dispose unused medications

Nearly 800 community pharmacies in 40 states are making it easier than ever for consumers to safely dispose of unused patient medications at their local pharmacy, the National Community Pharmacists Association and Sharps Compliance, Inc. announced today.

20 Apr 2010

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus.

20 Apr 2010

Genentech to pay Seattle Genetics $9.5M for renewing licenses under existing ADC collaboration agreement

Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.

20 Apr 2010

NextBio announces new Sequence-Centric module for mining high throughput array and sequencing data

NextBio today announced the latest evolution of its innovative life science research platform, adding new capabilities for the integration and mining of high-throughput array and next-generation sequencing data. The new NextBio Sequence-Centric module enables researchers to effectively explore and utilize massive amounts of public and internally generated sequencing data, while allowing organizations to create corporate-wide genomic data platforms to serve the needs of their global research teams.

20 Apr 2010

Researchers find no correlation between AED drug load and number of adverse effects in epileptic patients

Researchers have found that polytherapy with multiple anti-epileptic drugs did not result in greater adverse effects than monotherapy for patients with refractory epilepsy. This observational study also found AED load was not a factor in causing adverse effects, but suggests that individual susceptibility, type of AEDs used, and physicians' skills determine which patients suffer adverse effects.

20 Apr 2010

Global guidelines for testing regimes for breast cancer patients

A cancer research specialist from the University of the West of England, Bristol is one of a panel of international experts who have had a report published in the Journal of Clinical Oncology today that gives new global guidelines for testing regimes for breast cancer patients. The guidelines relate to cancer patients with oestrogen and progesterone receptor positive breast tumours.

20 Apr 2010

Forgetfulness, procrastination related to prescription drugs costs $163 billion in wasteful healthcare spending

Express Scripts is the first organization ever to quantify the hidden healthcare costs of very common behaviors related to prescription drugs, such as forgetfulness and procrastination, estimating the annual wasteful spending at $163 billion.

20 Apr 2010

AstraZeneca/Targacept's TC-5214 for treatment resistant depression to earn Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018.

20 Apr 2010

Magnetically guided nanoparticles for delivering DNA, cells and drugs

Scientists and engineers have used uniform magnetic fields to drive iron-bearing nanoparticles to metal stents in injured blood vessels, where the particles deliver a drug payload that successfully prevents blockages in those vessels. In this animal study, the novel technique achieved better results at a lower dose than conventional non-magnetic stent therapy.

20 Apr 2010

Global pharmaceutical market to reach $1.1 trillion in 2014: IMS Health

IMS Health reported today that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion over the next five years, reaching $1.1 trillion in 2014. The 5 - 8 percent compound annual growth rate during this period reflects the impact of leading products losing patent protection in developed markets, as well as strong overall growth in the world's emerging countries.

20 Apr 2010

Researchers use genistein to improve outlook of pancreatic cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 101st Annual Meeting 2010 that shows when genistein, a component of soy, is paired with the FDA-approved drug oxaliplatin, pancreatic cancer cells become more sensitive to chemotherapy.

20 Apr 2010

Dimerix Bioscience announces research agreement with Takeda Cambridge

Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of 'best in class' lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company.

20 Apr 2010

Momenta Pharmaceuticals presents preclinical data of M402 at AACR 2010

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model.

20 Apr 2010

New research shows link between infection-related diseases and risk of cancer

New research is emerging that suggests a link between infection-related diseases and risk of cancer, according to findings presented here at the American Association for Cancer Research 101st Annual Meeting 2010.

20 Apr 2010

Array BioPharma signs agreement with Novartis for worldwide development of ARRY-162

Array BioPharma Inc. today announced that it has entered into an agreement with Novartis for the worldwide development of the small-molecule MEK inhibitors ARRY-162, currently in a Phase 1 cancer trial, its back-up, ARRY-300, and other MEK inhibitors.

20 Apr 2010

FTO gene associated with loss of brain tissue: UCLA researchers

Three years ago, geneticists reported the startling discovery that nearly half of all people in the U.S. with European ancestry carry a variant of the fat mass and obesity associated gene, which causes them to gain weight - from three to seven pounds, on average - but worse, puts them at risk for obesity.

20 Apr 2010

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

In the first study of vitamin K and Non-Hodgkin lymphoma risk, researchers at the Mayo Clinic campus in Minnesota have found that people who have higher intakes of vitamin K from their diet have a lower risk of developing Non-Hodgkin lymphoma.

20 Apr 2010

Drugs News and Research

Researchers identify potential drug target for treatment of Alzheimer's disease

Positive top-line results from Phenomix' Phase 3 trial of dutogliptin for Type 2 diabetes mellitus

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

Pharmacies launch Dispose My Meds campaign to help consumers safely dispose unused medications

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

Genentech to pay Seattle Genetics $9.5M for renewing licenses under existing ADC collaboration agreement

NextBio announces new Sequence-Centric module for mining high throughput array and sequencing data

Researchers find no correlation between AED drug load and number of adverse effects in epileptic patients

Global guidelines for testing regimes for breast cancer patients

Forgetfulness, procrastination related to prescription drugs costs $163 billion in wasteful healthcare spending

AstraZeneca/Targacept's TC-5214 for treatment resistant depression to earn Decision Resources' gold standard status

Magnetically guided nanoparticles for delivering DNA, cells and drugs

Global pharmaceutical market to reach $1.1 trillion in 2014: IMS Health

Researchers use genistein to improve outlook of pancreatic cancer

Dimerix Bioscience announces research agreement with Takeda Cambridge

Momenta Pharmaceuticals presents preclinical data of M402 at AACR 2010

New research shows link between infection-related diseases and risk of cancer

Array BioPharma signs agreement with Novartis for worldwide development of ARRY-162

FTO gene associated with loss of brain tissue: UCLA researchers

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News